In a recent retrospective trial, 491 patients were included where Aldafermin showed a dose-dependent reduction in liver fat content, alanine aminotransferase levels (ALT), aspartate aminotransferase levels (AST) and enhanced liver fibrosis scores, in the 1 mg and 3 mg subgroups [39]. This evidence concerns the gene GPT and Hepatic fibrosis.